Recent progress in sodium channel modulators for pain

被引：138
作者：
Bagal, Sharan K. [1 ]
Chapman, Mark L. [2 ]
Marron, Brian E. [3 ]
Prime, Rebecca [4 ]
Storer, R. Ian [1 ]
Swain, Nigel A. [1 ]
机构：
[1] Pfizer Neusentis, Worldwide Med Chem, Cambridge CB21 6GS, England
[2] Pfizer Neusentis, Electrophysiology, Durham, NC USA
[3] Pfizer Neusentis, Chemistry, Durham, NC USA
[4] Pfizer Neusentis, Electrophysiology, Cambridge CB21 6GS, England
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 16期
关键词：
Voltage-gated sodium channels; Electrophysiology screening; Sodium channel toxins; Sodium channel structure; Sodium channel drugs; OF-FUNCTION MUTATIONS; HUWENTOXIN-IV; CRYSTAL-STRUCTURE; DRUG DISCOVERY; NA+ CURRENT; PROTX-II; INHIBITOR; TETRODOTOXIN; MECHANISMS; POTENT;
D O I：
10.1016/j.bmcl.2014.06.038
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Voltage-gated sodium channels (Na(v)s) are an important family of transmembrane ion channel proteins and Na-v drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda (R), Synchropatch (R) and Qube (R). Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery. (C) 2014 The Authors. Published by Elsevier Ltd.
引用
收藏
页码：3690 / 3699
页数：10
相关论文
共 88 条
  • [1] Andrez J.-C., 2013, [PCT Int. Appl, WO], Patent No. [WO 2013177224, 2013177224]
  • [2] Bagal S., 2013, [PCT Int. Appl., WO], Patent No. [WO 2013061205, 2013061205]
  • [3] Bagal S. K., 2013, WO patent, Patent No. [WO 2013114250, 2013114250, 2013/114250]
  • [4] Advances in patch clamp technique: towards higher quality and quantity
    Bebarova, Marketa
    [J]. GENERAL PHYSIOLOGY AND BIOPHYSICS, 2012, 31 (02) : 131 - 140
  • [5] Bell A. S., 2012, [PCT Int. Appl., WO], Patent No. [WO 2012095781, 2012095781]
  • [6] Blair NT, 2003, J NEUROSCI, V23, P10338
  • [7] Boezio C., 2013, Patent No. [WO 2013086229, 2013086229, WO 2013086229A1]
  • [8] Boezio C., 2013, [PCT Int. Appl, WO], Patent No. [WO 2013122897, 2013122897]
  • [9] Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain
    Bregman, Howard
    Berry, Loren
    Buchanan, John L.
    Chen, April
    Du, Bingfan
    Feric, Elma
    Hierl, Markus
    Huang, Liyue
    Immke, David
    Janosky, Brett
    Johnson, Danielle
    Li, Xingwen
    Ligutti, Joseph
    Liu, Dong
    Malmberg, Annika
    Matson, David
    McDermott, Jeff
    Miu, Peter
    Hanh Nho Nguyen
    Patel, Vinod F.
    Waldon, Daniel
    Wilenkin, Ben
    Zheng, Xiao Mei
    Zou, Anruo
    McDonough, Stefan I.
    DiMauro, Erin F.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (13) : 4427 - 4445
  • [10] Brown A. D., 2012, [PCT Int. Appl., WO], Patent No. [WO 2012007868, 2012007868]
123456789